Compound class:
Synthetic organic
Comment: LY3509754 is an orally bioavailable, small molecule inhibitor of the proinflammatory cytokine IL-17A [1]. It was intended as an alternative to anti-IL-17A monoclonals for the treatment of psoriasis.
|
|
Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|